Olaparib Does Not Improve Outcomes in Platinum-Ineligible Metastatic Urothelial Carcinoma
Adding olaparib to durvalumab did not improve progression-free or overall survival.
Diagnosis & Disease Information
Data Support Trimodal Therapy for Muscle-Invasive Bladder Cancer
A propensity-score matched comparison revealed no significant difference in oncologic outcomes between radical cystectomy and trimodal therapy.
Anemia Ups Risk for Radical Cystectomy Complications
Anemia can identify patients at higher risk for radical cystectomy complications and may be useful in preoperative counseling, according to investigators.
Second Primary Cancers Less Likely With IMRT vs CRT for Prostate Tumors
Among patients receiving radiation therapy (RT) for prostate cancer, intensity-modulated radiation therapy is significantly associated with a reduced risk for second primary solid malignancies compared with 3D conformal RT.
Tislelizumab Shows Promise for High-Risk Nonmuscle-Invasive Bladder Cancer
Investigators observed a complete response in more than half of patients treated with tislelizumab plus nab-paclitaxel for high-risk NMIBC that was not completely resectable.
Novel Agent N-803 Safe, Effective for BCG-Unresponsive High-Risk NMIBC
Investigators sought to determine the efficacy and safety of N-803 plus BCG in patients with high-risk NMIBC.
Erectile Function Prior to Nerve-Sparing RC Affects Return to Potency
Men undergoing radical cystectomy are most likely to recover erectile function if they have good function before the surgery and receive nerve-sparing, according to investigators.
Adjuvant Nivolumab Shows Durable Benefit in High-Risk MIUC
Longer follow-up from the CheckMate 274 trial shows nivolumab given after radical surgery for high-risk muscle-invasive urothelial carcinoma maintains a clinically meaningful improvement in disease-free survival.
Cessation Program in Cancer Clinics May Reach More Tobacco Smokers
Low-burden, point-of-care program may increase access to and impact of treatment to assist tobacco cessation
Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...